Florida-based e-cigarette manufacturer Bidi Vapor has taken the US Food and Drug Administration (FDA) to court claiming it suffered “continued irreparable harm” from being given a marketing denial order (MDO) for its vaping products – despite the agency having put the company’s application back under review.
A motion for “stay pending review” filed with the US Court of Appeals for the Eleventh Circuit in Atlanta, Georgia claims Bidi faces “immense financial losses” as a result of the MDO issued by the FDA in response to its premarket tobacco product application (PMTA).
Get access to premium content that is normally only available for subscribers.
For the duration of a week, you can read our news analysis, identify market trends and understand upcoming changes in the industry, which will enable you to get ahead of your competitors.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the ECigIntelligence team.